Pharmaceutical expenditure control in Europe: time to move from pricing to budgeting?

Garattini, Livio

doi:10.1177/0141076819894681

Cited by 4 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…in outpatient services in Organisation for Economic Co-operation and Development (OECD) countries. For other medications (other than antibiotics), the amount would be paid by customers as co-payment (through out of pocket or supplementary health insurance) is minor, (from A 41$ up to A 1486.8$ per year in Australia, up to a maximum of 10% of prescription costs in Germany, copayment for up to SEK 58 per prescription and up to 2460 SEK (Swedish krona) per year in Norway, up to 10% for cheap medicines and up to 20% for expensive medicines in Switzerland and co-payment up to 12% in the United Kingdom) (33)(34)(35)(36)(37).…”

Section: Article Search Resultsmentioning

confidence: 99%

Estimation of the Cost-Saving for Inpatient and Pharmaceutical Expenses if a Diagnostic Related Group Payment System Had Been Established Instead of Fee-for-Service and Case-Mixed Payment Systems

Khadivi

Meybodi

Saghafi

et al. 2022

Preprint

View full text Add to dashboard Cite

Introduction: The second phase of Universal Health Coverage (UHC) was implemented in Iran in 2014. The purpose of this study was to estimate the amounts of cost-saving in inpatient and pharmaceutical costs in public hospitals if the Diagnostic Related Groups (DRG) payment system had been implemented instead of the Fee-for-Service (FFS) and Case-mixed payment systems. Methods In this cross-sectional study, firstly, the inpatient and pharmaceutical costs were collected in public hospitals, affiliated with Isfahan University of Medical Sciences (MUI), in 2013 and 2015. In the second stage, according to a systematic review study by August 2021, the average effects of establishing the DRG payment system on the costs of inpatient and pharmaceutical services were extracted. In the third stage, taking into account the inflation rate, this presumptive average effects of the DRG (based on global models) incurred in the MUI’s public hospitals expenses. In this way, it was estimated the amount of money that could be saved if the DRG payment system has been implemented. Results According to the related published papers, following implementation of the DRG, the medication and hospitalization costs nearly decreased by average as 40.86% and 16.39%, respectively. By applying the assumption ratio of change following the implementation of the DRG, the cost savings were estimated as 119,679,523$ and 146,357,651$ in inpatient and pharmaceutical expenses respectively. Conclusion During the UHC, if the DRG payment system had been implemented, it could be saved 17.43% of the total expenditures incurred in the health sector of MUI.

show abstract

Section: Article Search Resultsmentioning

confidence: 99%

Estimation of the Cost-Saving for Inpatient and Pharmaceutical Expenses if a Diagnostic Related Group Payment System Had Been Established Instead of Fee-for-Service and Case-Mixed Payment Systems

Khadivi

Meybodi

Saghafi

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Livio Garratini and Anna Padula explain why the current model of drug pricing is broken. 2 The era of austerity in public funding is in direct opposition to the pharmaceutical industry's desire to set high prices for its drugs and maximise profits. A five-step system of 'rational budgeting' on a national scale is their answer.…”

mentioning

confidence: 99%